Details

Autor(en) / Beteiligte

• Rocconi, Rodney P
• Stanbery, Laura
• Tang, Min
• Walter, Adam
• Monk, Bradley J
• Herzog, Thomas J
• Coleman, Robert L
• Manning, Luisa
• Wallraven, Gladice
• Horvath, Staci
• Bognar, Ernest
• Senzer, Neil
• Brun, Scott
• Nemunaitis, John

Titel

ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer

Ist Teil von

• Communications medicine, 2022-08, Vol.2 (1), p.106-9, Article 106

Ort / Verlag

England: Springer Nature B.V

Erscheinungsjahr

2022

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Broadened use of predictive molecular and phenotypic profiling amongst oncologists has facilitated optimal integration of targeted- and immuno-therapeutics into clinical care. However, the use of predictive immunomarkers in ovarian cancer (OC) has not consistently translated into clinical benefit. Vigil (gemogenovatucel-T) is a novel plasmid engineered autologous tumor cell immunotherapy designed to knock down the tumor suppressor cytokines, TGFβ1 and TGFβ2, augment local immune function via increased GMCSF expression and enhance presentation of clonal neoantigen epitopes. Methods: All patients enrolled in the VITAL trial (NCT02346747) of maintenance Vigil vs. placebo as front-line therapy with homologous recombination proficient (HRP) stage IIIB-IV newly diagnosed ovarian cancer underwent NanoString gene expression analysis. Tissue was obtained from surgically resected ovarian tumor tissue following surgical debulking. A statistical algorithm was used to analyze the NanoString gene expression data. Using the NanoString Statistical Algorithm (NSA), we identify high expression of (which functions as the rate-limiting step in the production of the immune suppressor adenosine from ATP to ADP) as a presumptive predictor of response to Vigil versus placebo regardless of HRP status on the basis of relapse free survival (median not achieved vs 8.1 months,  = 0.00007) and overall survival (median not achieved vs 41.4 months,  = 0.013) extension. NSA should be considered for application to investigational targeted therapies in order to identify populations most likely to benefit from treatment, in preparation for efficacy conclusive trials.